Dulaglutide or Tirzepatide, hepatitis C treatment, long COVID-19 treatment, and biopharma updates

Voices and Opinion
Written By Christina Acosta

This week's topics include dulaglutide or tirzepatide, hepatitis C treatment, drugs for fatigue in long Covid, and biopharma changes around the world.

Program notes:

0:38 Migrating biopharma industry

1:36 Early stage development

2:36 Need to replicate studies

3:23 Treatment for fatigue from long Covid

4:25 Fluvoxamine or metformin

5:25 Only fluvoxamine helped

6:25 Only for fatigue

6:35 How treatments for hepatitis C have been used

7:36 Number of people receiving treatment declining

8:36 Need a better system

9:16 Dulaglutide or tirzepatide and patient reported outcomes

10:17 Quality of life metrics

11:43 End

Christina Acosta
Next

Cooking and dementia, asymptomatic aortic stenosis, pediatric sepsis, and high-dose versus standard-dose flu vaccines